citybiz – Questions & Answers with Sean A. MacDonald, Chief Executive Officer at Kainova Therapeutics

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

Rescuing a Rare Disease Trial: Accelerating MRCT RA Submissions for a Taiwan Biotech Company

This case study highlights HiRO's effective intervention in accelerating the regulatory submission process for a…